E3 Ligase Ligands for PROTACs:How They Were Found and How to Discover New Ones by Ishida, Tasuku & Ciulli, Alessio
                                                                    
University of Dundee
E3 Ligase Ligands for PROTACs
Ishida, Tasuku ; Ciulli, Alessio
Published in:
SLAS Discovery
DOI:
10.1177/2472555220965528
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ishida, T., & Ciulli, A. (2020). E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover
New Ones . SLAS Discovery, 1-19. https://doi.org/10.1177/2472555220965528
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 11. Nov. 2020
https://doi.org/10.1177/2472555220965528
SLAS Discovery
 1 –19
© The Author(s) 2020
DOI: 10.1177/24 2555220965528
journals.sagepub.com/home/jbx
Perspective
Introduction
Selective modulation of targeted proteins with small mole-
cules is a major strategy to treat disease. In the early 2000s, 
almost all pharmaceutical companies invested heavily in 
efforts to develop small-molecule protein modulators, 
mainly inhibitors, with desirable properties in terms of effi-
cacy and safety. Although a lot of new molecular entities 
(NMEs) were launched as a result, numerous proteins 
remain poorly tractable and so challenging to tackle by 
small molecules. New modalities, such as antibody and oli-
gonucleotides, opened a door to address some of those more 
challenging targets, but face other limitations such as poor 
cell permeability and/or chemical instability. Alternative 
small-molecule modalities are therefore required to expand 
the range of proteins being targeted for drug discovery.
Inducing degradation of target proteins by bifunctional 
small molecules, so-called proteolysis-targeting chimeras 
(PROTACs), is one of the most exciting such new modali-
ties. PROTACs consist of a ligand for recruiting a target 
protein of interest (POI) and a ligand for an E3 ubiquitin 
ligase, joined with an appropriate linker. PROTACs induce 
proximity between an E3 ligase and POI in the form of a 
ternary complex that results in POI ubiquitination and sub-
sequent degradation by the proteasome (Fig. 1). Compared 
with classical inhibition by small molecules, PROTACs 
offer several potential advantages: (1) PROTACs are 
expected to exert similar phenotypes to those observed via 
knockdowns using genetic tools, such as small interfering 
RNA (siRNA), short hairpin RNA (shRNA), or clustered 
regularly interspaced short palindromic repeats (CRISPR), 
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Abstract
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical 
tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding 
to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–
proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands, notably for von Hippel–Lindau (VHL) 
and cereblon (CRBN), revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective 
degradation activity. A first wave of PROTAC drugs are now undergoing clinical development in cancer, and the field 
is seeking to extend the repertoire of chemistries that allow hijacking new E3 ligases to improve the scope of targeted 
protein degradation.
Here, we briefly review how traditional E3 ligase ligands were discovered, and then outline approaches and ligands that have 
been recently used to discover new E3 ligases for PROTACs. We will then take an outlook at current and future strategies 
undertaken that invoke either target-based screening or phenotypic-based approaches, including the use of DNA-encoded 
libraries (DELs), display technologies and cyclic peptides, smaller molecular glue degraders, and covalent warhead ligands. 
These approaches are ripe for expanding the chemical space of PROTACs and usher in the advent of other emerging 
bifunctional modalities of proximity-based pharmacology.
Keywords
PROTACs, E3 ubiquitin ligase, targeted protein degradation, binding ligands, molecular glues
2 SLAS Discovery 00(0)
because the downstream result is the same in all those cases 
(i.e., depletion of intracellular protein levels). Elimination 
of POI could give additional effect by disrupting formation 
of biologically functional complexes. (2) PROTACs can 
work catalytically (i.e., can be recycled so that one PROTAC 
molecule can turn over multiple molecules of POI) and so 
can act “sub-stoichiometrically” (i.e., at fractional occu-
pancy of the POI). As a result of this, PROTACs often show 
higher POI degradation than expected based on their bind-
ing affinity to the POI alone. (3) Target protein degradation 
by PROTACs can suppress resistant mutation and/or upreg-
ulation of POI.
In 2001, Sakamoto and coworkers reported a first 
PROTAC to degrade methionine aminopeptidase (MetAP),1 
and in 2004, Schneekloth et al. described peptidic von 
Hippel–Lindau tumor suppressor (pVHL) protein-based 
PROTACs, which showed cellular permeability and degra-
dation activity against FK506 binding protein 12 (FKBP12) 
and androgen receptor (AR).2 These first-generation 
PROTACs consisted of a peptidic ligand for an E3 ligase. 
Peptide moieties caused limited cell permeability, synthetic 
tractability, and biological instability, which motivated 
efforts to develop more drug-like, nonpeptidic E3 ligase 
ligands. During the past few years, these efforts have 
resulted in improved small-molecule-based PROTACs 
recruiting cereblon (CRBN),3 von Hippel–Lindau (VHL),4 
and inhibitors of apoptosis proteins (IAPs).5 By leveraging 
these small-molecule E3 ligase ligands, the field has since 
extensively demonstrated that PROTACs can induce degra-
dation of a variety of proteins, even at sub-nanomolar con-
centrations, and has validated their applications not only as 
biological tools but also as a new chemical modality for 
treatment of diseases in the clinic. Moreover, modern 
medicinal chemistry efforts have enabled the development 
of PROTACs with acceptable drug-like properties. In 2020, 
Arvinas presented interim results of a Phase 1/2 clinical 
trial of their front-line PROTAC, ARV-110, in men with 
metastatic castration-resistant prostate cancer (mCRPC) 
and showed two patients achieving responses in prostate-
specific antigen (PSA) levels.6,7 This landmark result 
showed pharmacological efficacy of PROTACs in the 
clinic. The number of E3 ligases currently being explored 
by the most advanced PROTAC molecules remains small 
(typically, VHL, CRBN, and IAPs), however, limiting 
scope. Expansion of the E3 ligase toolbox will therefore be 
important not only to facilitate degrading a broader range of 
proteins but also to potentially induce less systemic and 
more selective (e.g., tissue- or organ-specific) degradation 
of target proteins by exploiting differential biology and 
expression levels of E3 ligases.
Here, we first briefly recount how ligands of the typical 
E3 ligases for PROTACs were discovered, and then review 
approaches that have been recently used to discover new 
ligands and new E3 ligases for PROTACs. We then outline 
the diverse technologies that, in our opinion, provide the 
most compelling and suited strategies to find new E3 ligase 
ligands for PROTACs, including applications of structure-
based ligand design, DNA-encoded libraries (DELs), dis-
play technologies for macrocyclic peptides, molecular 
glues, and covalent warhead ligands.
Discovery of the Traditional E3 Ligase  
Ligands for PROTACs
VHL Ligands and Applications to PROTACs. In 1992, the 
hypoxia-inducible factor-1α (HIF1α) was found in Hep3B 
cells as a factor inducing erythropoietin under hypoxic condi-
tions.8 After this finding, it was discovered that HIF1α also 
regulates a variety of biological responses (e.g., metabolic 
reprogramming,9 suppression of reactive oxygen species 
Figure 1. Graphical 
representation of the 
degradation mechanism of 
proteolysis-targeting chimeras 
(PROTACs).
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[ROS] production,10 angiogenesis,11 epithelial-mesenchymal 
transition,12 and cancer metastasis13). Under normoxic condi-
tions, intracellular concentrations of HIF1α are kept at low 
levels by hydroxylation of specific proline residues and sub-
sequent ubiquitination and proteasomal degradation. The 
protein responsible for this process was later found to be the 
pVHL protein, a tumor suppressor protein mutated in VHL 
disease.14,15 pVHL is a subunit of the E3 ubiquitin ligase 
CUL2–RBX1–ElonginB–ElonginC–VHL (CRL2VHL) com-
plex.16–18 The cocrystal structure of the pVHL complex and 
C-terminal oxygen-dependent degradation (CODD) motif of 
HIF1α revealed the structural recognition of a key hydroxy-
proline residue in hydroxylated HIF1α by pVHL.19,20
Early PROTACs consisted of epitope peptide CODD 
motif (ALAPYIP) conjugated to a poly-D-arginine tag at 
the C-terminus, and to a target binding ligand at the 
N-terminus. These peptidic PROTACs induced degradation 
of intracellular FKBP12 and AR without need of microin-
jection, albeit at fairly high concentrations.2 The moiety of 
the peptidic pVHL ligand, however, limited further applica-
tion as mentioned before; therefore, development of non-
peptidic pVHL ligands was required to overcome this issue.
In 2012, novel peptidomimetic pVHL ligands were 
developed by the laboratories of Crews and Ciulli, by lever-
aging the hydroxyproline core fragment that forms critical 
binding interactions with Ser111 and His115 in the hydroxy-
proline binding pocket on pVHL. Computational approaches 
to design plausible ligands and subsequent cocrystal struc-
tures guided rational medicinal chemistry optimization that 
yielded a first small-molecule pVHL–HIF1α protein– 
protein interaction inhibitor with dissociation constants of 
single-digit micromolars.21–23 Galdeano et al. later devel-
oped second-generation ligands via structure-based drug 
design using cocrystal structures and isothermal titration 
calorimetry (ITC) to optimize, in a stepwise rational fashion, 
interactions at the left-hand side of the VHL ligand. As a 
result of their optimization study, strong VHL binders with 
nanomolar binding affinity to VHL were finally obtained, 
disclosing VHL ligand VH032 (Fig. 2A).24 Subsequent 
medicinal chemistry work by the Ciulli group optimizing the 
“capping group” at the left-hand side of VH032 found that 
this position is tolerant for and can accommodate a variety 
of substituents. They identified fluoro- and cyano-cyclopro-
pyl capping groups, which led to novel compounds (VH101 
and VH298, respectively; Fig. 2A) with sub-100 nM affinity 
(more potent affinity than a 10-mer HIF1α peptide).25 
Biophysical and cellular studies qualified VHL inhibitor 
VH298 as a potent, selective, and cell-active chemical probe 
of the hypoxic signaling pathway.26
The left-hand side of the VHL ligands provided an early 
suitable exit vector to develop PROTACs. Zengerle et al. 
leveraged the crystal structure of VH032 bound to VHL to 
design and develop one of the first VHL-based PROTACs, 
MZ1 (Fig. 2A), which degraded Bromodomain- and 
Extraterminal domain (BET) proteins BRD2, BRD3, and 
BRD4 in cancer cells, with unexpectedly selective degrada-
tion for BRD4 at single- to double-digit nanomolar levels.4 
At the same time, Bondeson et al. independently reported 
PROTACs bearing the same VHL ligand that degraded estro-
gen-related receptor-α (ERRα) and Receptor-interacting ser-
ine/threonine-protein kinase-2 (RIPK2) efficiently both in 
cells and in vivo (PROTAC_RIPK2 and PROTAC_ERRα; 
Fig. 2A).27 These two studies disclosed the first high-quality 
all-small-molecule VHL-based PROTACs, changing the 
game in the field and opening future avenues for VHL-based 
and other E3-recruiting PROTACs.
Ligands for CRBN and Application to PROTACs. In 1957, tha-
lidomide (Fig. 2B) was launched by Chemie Grünenthal as 
a drug for insomnia. Shortly following administration and 
use as a sedative, however, it was found that thalidomide 
had strong teratogenicity, causing approximately 8000 to 
12,000 children to be born with deformities.28 After those 
tragic adverse events, thalidomide was finally withdrawn 
from the market. Fifty years later, thalidomide was found to 
have therapeutic effect in patients with multiple myeloma,29 
but the mechanism of action remained unclear. In 2010, Ito 
et al. found that thalidomide binds to CRBN, a subunit of 
the E3 ubiquitin ligase CUL4–RBX1–DDB1–CRBN 
(CRL4CRBN), and CRBN engagement induced at least part 
of the teratogenic effect in in vivo models.30 Two indepen-
dent groups then separately reported that lenalidomide, a 
derivative of thalidomide and a marketed drug used for the 
treatment of hematological malignancies, induced degrada-
tion of transcription factor Ikaros family zinc finger pro-
tein-1 (IKZF1) and Ikaros family zinc finger protein-3 
(IKZF3).31,32 In 2014, two X-ray cocrystal structures of 
DDB1–CRBN–thalidomide complexes were disclosed by 
the laboratories of Thomä and Celgene. The structures 
revealed that a portion of the phthalimide ring on thalido-
mide is exposed to solvent and provided room for extending 
a substituent or linker.33,34 In a manner similar to that pur-
sued with VHL-based PROTACs, Winter et al. and Lu et al. 
leveraged these findings and crystal structures to develop 
PROTACs dBET1, ARV825, and dFKBP (Figure 2B), 
which potently and rapidly degraded BET proteins or 
FKBP12 and demonstrated tumor growth inhibitory activity 
in cells and in mouse models.3,35
CRBN and VHL: Key Players in the PROTAC Field. Currently, 
the VHL and CRBN ligands are the most popular and most 
frequently used E3 ligands to design PROTAC degraders. 
These ligands are the frontrunners in this field because of 
several favorable features: (1) strong, specific, and biophys-
ically validated binding affinities to their targeted E3 ligase; 
(2) acceptable physicochemical profile, for example molec-
ular weight, lipophilicity, solubility, lack of obvious reac-
tive groups or metabolic hotspots, and lack of pan-assay 
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interference compounds (PAINS)36 alerts; and (3) well-
characterized structural information of their binding modes. 
Because of these properties, numerous PROTACs that are 
based on CRBN or VHL have been reported that have 
shown excellent in vitro and in vivo degradation activities 
for the targeted POI (Fig. 2). As a result, PROTACs com-
posed of CRBN or VHL ligand are currently considered one 
of the most powerful alternative modalities of chemical 
intervention into biology and promising therapeutics. 
Therefore, not only Big Pharma but also institutes and bio-
tech firms have filed many patents and are engaged in 
developing PROTACs all the way into the clinic (Fig. 3).
PROTACs Based on IAP Ligands. The family of IAPs is char-
acterized by three baculovirus IAP repeat (BIR) domains at 
their N-termini, and has important functions in inhibiting 
Figure 2. Von Hippel–Lindau (VHL)-based and cereblon (CRBN)-based small-molecule proteolysis-targeting chimeras (PROTACs). 
(A) Exemplified structures of VHL ligands and the PROTACs composed of them: VH032,24,26 VH101,25 VH298,25,26 MZ1,4 PROTAC_ 
RIPK2,27 PROTAC_ ERRα,27 ARD-266,137 VZ185,77 and ACBI1.138 (B) Exemplified structures of thalidomide and PROTACs composed 
of CRBN ligands: thalidomide,28 dBET1,3 dFKBP12,3 QCA570,139 PROTAC6,140 ZNL-02-096,141 and d9A-2.142
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cell apoptosis. Five out of eight IAPs, including cellular 
inhibitor of apoptosis-1 (cIAP1) and X-linked inhibitor of 
apoptosis protein (XIAP), also contain Really Interesting 
New Gene (RING) domains that bind to E2 conjugating 
enzymes, and so act as E3 ligases. Sekine et al. reported that 
methyl bestatin (MetBS; Fig. 4A) binds to the BIR3 domain 
of cIAP1 and induces self-ubiquitination following protea-
somal degradation of cIAP1.37 Structure–activity relation-
ship studies of MetBS suggested that the bestatin portion 
binds to cIAP1, while the methyl ester is solvent exposed. 
Based on this observation, bifunctional small molecules 
were developed that comprise bestatin and all-trans retinoic 
acid (ATRA) linked by a polyethylene glycol (PEG) linker. 
These compounds were found to induce degradation of cel-
lular retinoic acid binding protein-2 (CRABP2) (SNIPER2 
and SNIPER4; Fig. 4A).5,38 The authors named this tech-
nology Specific and Nongenetic Inhibitor of Apoptosis Pro-
tein (IAP)-Dependent Protein Eraser (SNIPER) and later 
expanded it to other target proteins, such as estrogen recep-
tor (ER),39 BRD4,40 and BCR-ABL41 [SNIPER(ER)-87, 
SNIPER(BRD4)-1, and SNIPER(ABL)-62; Fig. 4A]. One 
characteristic feature of SNIPERs is that they can retain 
self-ubiquitination activity toward cIAP1. This effect may 
show synergistic activity to types of cancer cells in which 
cIAP1-induced degradation is beneficial. The self-degrada-
tion effect, however, reduces intracellular levels of cIAP1 
and consequently causes suppression of degradation activ-
ity toward the target protein.42
PROTACs Based on MDM2 Ligands. Tumor protein p53 is a 
transcription factor that regulates DNA repair, cell cycle, 
and apoptosis. p53 is mutated in more than 50% of can-
cers.43 Mouse double minute 2 homolog (MDM2) protein is 
an E3 ubiquitin ligase that induces ubiquitination of p53 
and subsequent proteasomal degradation of p53. Nutlin 
(Fig. 4B) is a well-known compound that binds to MDM2 
and disrupts MDM2–p53 interaction, and it is among the 
first small molecules that were discovered to bind to E3 
ligase proteins.44 In 2008, Schneekloth and coworkers 
developed a nonpeptidic PROTAC that consisted of an AR 
ligand and the nutlin motif (PROTAC 14; Fig. 4B).45 Some 
more PROTACs based on nutlin or idasanutlin46 were later 
Figure 3. Representative structures and biological data of recently disclosed patents: 406,143 I-685,144 Compound 1,145 Example 9,146 
and STEAP1-L1BC8.147
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Figure 4. Inhibitor of apoptosis protein (IAP)-based and mouse double minute 2 homolog (MDM2)-based proteolysis-targeting 
chimeras (PROTACs), and von Hippel–Lindau (VHL)-based and cereblon (CRBN)-based homo-PROTACs. (A) Exemplified structures 
of methyl bestatin (MetBS) and Specific and Nongenetic Inhibitors of Apoptosis Protein (IAP)-Dependent Protein Eraser (SNIPERs): 
MetBS,37 SNIPER-2 (R = O)5 and SNIPER-4 (R = NH),38 SNIPER(ER)-87,39 SNIPER(BRD4)-1,40 and SNIPER(ABL)-62.41 (B) Structures 
of MDM2 inhibitors and PROTACs incorporating with them: nutlin,44 idasanutlin,46 PROTAC 14,45 A1874,148 Compound 3,149 and 
MD-224.47 (C) Structures of homo-PROTACs and related PROTACs composed with CRBN and VHL ligands: CM11,48 Compound 
15a,49 CRBN-6-5-5-VHL,50 Compound 14a,51 and TD-165.52
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developed (Fig. 4B), but the number of MDM2 PROTACs 
has remained limited, due to their challenging physico-
chemical profile and limited degradation activity. PROT-
ACs composed of a ligand for CRBN linked to a ligand for 
MDM2 were found to potently degrade MDM2 protein 
selectively (MD-224; Fig. 4B).47 That implies that the deg-
radation efficiency and/or activity of MDM2 is supposed to 
be limited compared to the Cullin RING ligase complexes 
formed by CRBN or VHL.
Homo-PROTACs. The mode of action of PROTACs toward 
POIs was expanded by the development of unusual homo-
bifunctional molecules that comprised two ligands for the 
same E3 ligase. Maniaci et al. developed a novel type of 
PROTACs that were dimers of two VHL ligands joined by 
PEG linkers, so-called homo-PROTACs.48 The best com-
pound, CM11 (Fig. 4C), induced dimerization of CRL2VHL 
with high cooperativity (~20) in vitro and induced intracel-
lular VHL degradation at >100-fold lower concentration of 
the binary Kd value. CM11 also induced degradation of 
CUL2, suggesting a mechanism of bystander ubiquitination 
and degradation of a subunit different from that being 
recruited by the homo-PROTAC within the context of the 
whole CRL complex. Later, Steinebach et al. extended this 
approach to CRBN and developed homo-PROTACs that 
degrade CRL4CRBN ligase (Compound 15a; Fig. 4C).49 Two 
groups, Steinebach et al. and Girardini et al., then indepen-
dently reported hetero-bifunctional compounds that are 
composed with a ligand for CRBN at one end, and a ligand 
for VHL at the other end (CRBN-6-5-5-VHL and Com-
pound 14a; Fig. 4C). Both groups demonstrated that their 
PROTACs preferably induced the degradation of CRL4CRBN 
rather than CRL2VHL.50,51 The same finding was subse-
quently reported by a third group (TD-165; Fig. 4C).52 All 
three groups developed PROTAC degraders of slightly dif-
ferent chemical structures, yet in all cases preferential deg-
radation of CRBN was observed, suggesting that the 
homo-PROTAC approach could be used to hijack E3 ligases 
against each other for inducing selective E3 ligase 
degradation.
Expansion of the E3 Ligase Toolbox  
for PROTACs
Currently, PROTAC design and development center on the 
use of primarily VHL and CRBN ligands, and to some 
extent IAP ligands. There are, however, more than 600 E3 
ligases known to function in human cells, suggesting a large 
untapped pool of E3 ligases that are potentially hijackable 
for targeted protein degradation. To expand the scope of the 
PROTAC modality, efforts to expand the E3 ligase toolbox 
with novel chemistries have received significant efforts. 
Next, we briefly highlight the main progress from the past 
4–5 years at finding ligands for new E3 ligases.
KEAP1. Kelch-like ECH-associated protein-1 (KEAP1) is 
known to interact with nuclear factor erythroid 2-related 
factor-2 (Nrf2). The main function of KEAP1 is to regulate 
cellular responses for chemical and oxidative stress by its 
role as a substrate recognition subunit of a cullin-3 (CUL3) 
E3 ligase to bind to induce ubiquitination and degradation 
of substrate Nrf2.53 Academic and industrial groups have 
throughout the years developed a variety of small molecules 
that disrupt the KEAP1–Nrf2 interaction based on natural 
bioactive compounds,54–57 high-throughput screening 
(HTS),58–60 virtual screening,61,62 or fragment-based drug 
discovery (FBDD).63,64 In 2018, the first PROTACs recruit-
ing the KEAP1–CUL3 E3 ligase were reported that were 
shown to induce degradation of intracellular Tau at micro-
molar concentration.65 The peptidic nature of the PROT-
ACs, however, which used an Nrf2-based epitope peptide 
as KEAP1 ligand, limits their potential for expanding their 
use as in vivo tools for clinical application. Recently, Tong 
et al. developed the first nonpeptidic PROTACs that consist 
of JQ1 and bardoxolone methyl (CDDO-Me) as ligands of 
BET bromodomains and KEAP1, respectively (Fig. 5A).66 
They found that the degradation activity of BRD4 was 
diminished by removing the Michael acceptor motif of 
CDDO-Me, indicating that formation of covalent bonds 
between cysteines on KEAP1 and the Michael acceptor 
moiety on CDDO-Me is essential to recruit BRD4 to the 
KEAP1 E3 ligase.
DCAF15. Sulfonamide derivatives indisulam (E7070),67 
E7820,68 and chloroquinoxaline sulfonamide (CQS)69 were 
found to have antitumor activity and were tested in the clinic 
for the treatment of cancers (Fig. 5B). Yokoi et al. reported 
that a cancer cell line resistant to indisulam was also resis-
tant to E7820 and CQS, but not to doxorubicin and pacli-
taxel;70 however, the mechanism of action of those 
sulfonamide derivatives remained unclear for a long time. In 
2017, two groups, Uehara et al.71 and Ting et al.,72 indepen-
dently reported that these sulfonamides induce ubiquitina-
tion and subsequently proteasomal degradation of coactivator 
of activating protein-1 and estrogen receptors (CAPERα) 
via formation of a CAPERα–sulfonamide–DCAF15–
DDB1–CUL4 complex. In 2019, three independent groups 
released cocrystal structures of CAPERα–sulfonamide–
DCAF15–DDB1–DDA1 multimeric complexes and con-
firmed that sulfonamides induce formation of the complexes 
as a molecular glue.73–75 Their structural information could 
help to further optimize sulfonamides using structure-based 
drug design and leverage them as DCAF15 ligands for 
PROTAC design. Until recently, however, it has remained 
challenging to develop indisulam-based DCAF15-recruit-
ing PROTACs,76,77 most likely because of the weak binding 
affinities of these compounds to DCAF15 alone, or perhaps 
due to unsuitable orientation between the binding pocket of 
sulfonamides and the RING domain of CUL4.74 In 2020, Li 
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et al. reported a first aryl sulfonamide–based PROTAC, 
DP1 (Fig. 5B), that induces degradation of BRD4 and 
shows tumor growth inhibitory activity in mouse models in 
vivo. The biological activity of DP1 is limited, but the 
results demonstrate that DCAF15 can be applied for devel-
opment of PROTACs.78 Aryl sulfonamide derivatives have 
a good physicochemical profile (i.e., lower logD values and 
lower molecular weight compared to most E3 ligase ligands 
available); therefore, DCAF15 is likely to gain increased 
attention, and more DCAF15-mediated PROTACs are 
expected to be developed in the future.
Other E3 Ligases for PROTACs: RNF4, RNF114, DCAF16, and 
AhR. Unconventional approaches have shown promising 
applications to find new chemistry to expand the repertoire 
of E3 ligases for developing PROTACs. Ward et al. found 
novel covalent RNF4 binders by activity-based protein pro-
filing (ABPP)-based screening, and then their optimized 
ligand was applied to develop a novel type of PROTAC 
(CCW 28-3; Fig. 5C) to target BRD4 for degradation.79 
Around the same time, Spradlin and coworkers reported that 
nimbolide (Figure 5D), a natural compound that exhibits 
biological activities in cancer cells, was identified as a cova-
lent binder for the E3 ligase RNF114.80 In addition, they also 
developed a PROTAC that comprised nimbolide and JQ1 
(XH2; Fig. 5D), and demonstrated that it induced some deg-
radation activity of endogenous BRD4. Zhang et al. also 
synthesized hetero-bifunctional molecules consisting of a 
ligand for FKBP12 and three different electrophilic war-
heads, joined by a PEG linker.81 They treated HEK293T 
cells with those compounds and found that KB02-SLF (Fig. 
5E) showed moderate degradation activity on FKBP12. Pro-
teomics analysis and a following confirmatory pulldown 
SILAC (stable isotope labeling by amino acids in cell cul-
ture) experiment revealed that KB02-SLF degrades FKBP12 
via recruitment of CRL4DCAF16. Ohoka et al. also reported a 
Figure 5. Proteolysis-targeting chimeras (PROTACs) using nonconventional E3 ligase ligands. (A) Structures of CDDO-Me56,57 and 
CDDO-JQ1.66 (B) Structures of sulfonamide derivatives, indisulam,67 E7820,68 CQS,69 and DP1.78 (C) Structure of CCW 28-3.79  
(D) Structures of nimbolide and XH2.80 (E) Structure of KB02-SLF.81 (F) Structure of β-NF-ATRA.82
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PROTAC that uses a novel E3 ligase.82 They chose to focus 
on the arylhydrocarbon receptor (AhR) E3 ligase and devel-
oped PROTACs based on ligands of AhR. β-NF-ATRA (Fig. 
5F), a PROTAC that directed CRABPs, induced degradation 
of CRABP1 with AhR dependency, albeit with the fastidious 
effect of inducing self-degradation of AhR, akin to the mode 
of action of some SNIPERs.39–41
Target-Based Screening versus Phenotypic 
Screening Approaches
The exciting progress during the past few years in targeting 
E3 ubiquitin ligases with more drug-like small molecules, 
and in using them for developing cell-active PROTAC 
degraders, motivates the deployment of known, and the 
development of new, hit- and ligand-finding approaches to 
screen E3 ligases to discover new chemical matter against 
them.83 HTS against large compound collections is a well-
established approach to find hit compounds for “druggable” 
targets [e.g., kinases, G protein-coupled receptors (GPCRs), 
and ion channels]. HTS campaigns for finding ligands of E3 
ligases are not, however, straightforward. Among the rea-
sons are difficulties to select a proper readout to detect com-
pound activity against a targeted E3 ligase, because the 
ubiquitination activity of E3 ligases does not provide 
straightforward readouts that can be monitored in bioas-
says. Targeting of the substrate binding site of E3 ligases 
has shown much success for developing inhibitors and 
PROTACs (e.g., for VHL, CRBN, and IAPs), but that 
requires the disruption of protein–protein interactions, 
which are challenging targets for drug discovery.84 
Moreover, many substrate-binding pockets on E3 ligases 
and E3 substrate receptor subunits are shallow or highly 
charged, features that do not make them tractable targets 
with classical compound libraries. Because of the reasons 
mentioned above, and because for PROTAC development 
only binding ligands are needed, regardless of their inhibi-
tion activity on their own, other approaches are being devel-
oped and applied to find new binders of E3 ligases.
Fragment-Based Drug Design (FBDD) Approach. E3 ligands for 
PROTACs are not required to have functional activity in 
their own right against their targeted ligase. In principle, it 
suffices that they “bind” to a pocket or surface of the E3 
ligase, to provide a suitable starting point for the design of 
the bifunctional PROTACs. To this end, fragment-based 
screening is a gold standard method to find new binding 
pockets and new ligands for proteins. Lucas et al. screened 
more than 1200 small compounds that complied with the 
“rule of three”85 using differential scanning fluorometry 
(DSF) against the VHL–ElonginB–ElonginC complex of E3 
ligase.86 Primary hit compounds were validated by proton 
nuclear magnetic resonance (1H NMR) spectroscopy and 
X-ray crystal structure analysis, and then they identified 
three hit compounds that have weak but measurable binding 
affinity at two pockets distinct from the HIF1α recognition 
site: one involving the EloC–CUL2 interface, and the other 
one involving a previously unknown cryptic pocket in VHL. 
Fragment-based approaches were also applied to find non-
peptidic ligands for substrate recognition sites on E3 ligases. 
Researchers at Astex Pharmaceuticals conducted fragment 
library screening over IAPs and identified nonpeptidic hit 
compounds, even though their binding affinity to IAPs was 
in the weak millimolar range of dissociation constants.87 
They next elaborated hit compounds by structure-guided 
optimization and medicinal chemistry effort, and finally 
obtained ASTX660, which inhibits cIAP1 and XIAP at 
nanomolar levels (Fig. 6A).87–89 ASTX660 is currently in a 
Phase II trial being investigated for the treatment of advanced 
solid tumors and lymphomas.
Screening of noncovalent fragment libraries will con-
tinue to play a major role in our efforts to find suitable start-
ing points for E3 ligase ligand design. Fragment-based 
screening with small molecular covalent binders is emerg-
ing as an attractive approach too, however, and therefore 
should provide an alternative and powerful strategy to iden-
tify covalent binders at targetable hotspots of E3 ligases. 
Resnick and coworkers constructed a library of about 1000 
small fragments that have acrylamide or chloroacetamide as 
covalent-binding warheads.90 After validating their nonse-
lective reactivity to thiols, they screened them against 10 
proteins that have reactive cysteines by liquid chromatogra-
phy–mass spectrometry (LC-MS) analysis and identified 
two fragments that bind OTUB2 or NUDT7. In addition, a 
variety of covalent warheads for reactive amino acid resi-
dues were developed (Fig. 6B–6G), allowing us to expand 
the arsenal of covalent-binding small-molecule fragments.91 
As mentioned before, there are initial examples that 
PROTACs based on ligands that covalently bind to E3 
ligases were shown to have degradation activity for targeted 
proteins,65,78–80 and that means that weak covalent-binding 
fragments could be applied to develop novel PROTAC 
degraders. Therefore, these recent updates could help us to 
identify new covalent E3 ligase binders in the future.
Structure-Guided Drug Design Approach. Solving cocrystal 
structures of E3 ligases with fragment peptides of substrate 
proteins is also a major strategy to guide the design of small 
molecular binders of the ligase. A notable success of this 
approach has been the development of nonpeptidic ligands 
of VHL, as described in the section titled “VHL Ligands and 
Applications to PROTACs,” which combined information 
provided by the binding of the substrate HIF peptide with 
fragment-based ligand design. Solving more examples of 
cocrystal structures of other E3 ligases with corresponding 
fragment substrate peptides will therefore be important.
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SOCS2
Kung et al. reported cocrystal structures of suppressor of 
cytokine signaling-2 (SOCS2)–ElonginB–ElonginC com-
plexes with 11-residue phosphopeptides of erythropoietin 
receptor or growth hormone receptor that center their bind-
ing on the Tyr426 and Tyr595 regions, respectively.92 
Superposition of both cocrystal structures revealed essential 
key interactions of both substrate peptides to SOCS2 and 
now provide guiding features for designing nonpeptidic 
small ligands. Phosphotyrosine was found to have a respect-
able binding affinity for SOCS2 as a zwitterionic amino 
acid (in the 10−4 M range of dissociation constant), suggest-
ing that it could provide a suitable starting point for ligand 
design.93 The poor permeability of the negatively charged 
phosphotyrosine group will, however, impose some hurdles 
to be circumvented in their development as cell-active com-
pounds. In addition, a cocrystal structure of suppressor of 
cytokine signaling-6 (SOCS6) with a substrate peptide was 
reported.94
KLHL12
Kelch-like protein-12 (KLHL12) forms the CUL3–E3 ubiq-
uitin ligase complex, and it is known to negatively regulate 
the Wnt-signaling pathway by ubiquitination and subse-
quent proteasomal degradation against segment polarity 
protein Dishevelled homolog-3 (Dvl3). Zhao et al. mea-
sured binding affinity of several peptide fragments of 
C-terminal of Dvl3 to KLHL12 by 1H−15N heteronuclear 
single quantum coherence (HSQC) NMR analysis and iden-
tified the key peptide motif for binding to KLHL12.95 They 
then solved a cocrystal structure of KLHL12 with a trun-
cated peptide of Dvl3 and found important hydrophobic 
interaction of prolines with KLHL12.
Figure 6. Noncovalent and covalent fragment-based approaches for hit finding and ligand development for E3 ligases. (A) Initial 
hit compound to the final clinical compound, ASTX660.87–89 (B–F) Examples of specific residue-selective covalent warheads: (B) 
cysteine,150 (D) lysine,151 and (F) methionine;152 and (C,E,G) the reaction mechanisms.
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KLHDC2
Rusnac et al. reported cocrystal structures of Kelch domain–
containing protein-2 (KLHDC2), which is one of the BTB 
E3 ligases and acts as a substrate receptor of the CRL2 E3 
ligase complex, with an eight-amino-acid C-end degron 
peptide of substrate proteins.96 Those structures showed 
that these peptides were bound to the KLHDC2 pocket in a 
twisted conformation, and the C-terminal diglycine degron 
motif was fitted in a tight groove with strong coordination 
of the terminal carboxyl group via three highly conserved 
residues of KHDLC2.
GID4
Glucose-induced degradation protein-4 homolog (GID4) is 
one of the gastric inhibitory polypeptide (GIP) family and 
part of a GID family that composes the CTLH E3 ligase 
complex. GID4 recognizes N-terminal proline residues 
selectively in substrates to mark their ubiquitination and 
proteasomal degradation,97 but the mechanism of molecular 
recognition remained elusive. Dong et al. reported the 
cocrystal structures of the globular domain of GID4 with 
N-end proline fragments and observed that the terminal 
proline forms key interactions with the residues at the bot-
tom of a deep substrate binding pocket.98 In addition, the 
binding of degrons induces dynamic conformational change 
around the binding pocket to form hydrophobic interaction 
with the residues in the pocket.
There are other E3 ligases with reported 3D cocrystal 
structures containing ligands and proteins that have yet to be 
exploited for the development of PROTACs (Table 1). More 
structures of E3 ligases with or without bound substrates or 
small-molecule ligands are expected to be made available in 
the near future, and they could serve as a starting point for 
ligand development. Although some ligand-binding pockets 
seem unsuitable for designing peptidomimetic ligands for 
PROTACs (e.g., they have a wide and shallow binding area, 
or a highly charged pocket), a structure-based approach 
using structural information is one of the most attractive 
ways to design peptidomimetic ligands for disease-specific 
E3 ligases and apply them to PROTACs. Toward this goal, 
our laboratory collaborates as part of a large consortium 
named EUbOPEN (Enabling & Unlocking Biology in the 
OPEN), an Innovative Medicines Initiative (IMI)-funded 
project whose goal is to enable and unlock biology by 
developing chemical probes and ligands for novel protein 
Table 1. List of E3 Ligases for Which 3D Crystal Structures Are Reported with Bound Ligands or Partner Substrate Proteins, but 
That Are Yet to Be Explored for PROTAC Applications.
E3 Ligase Class Ligand Pocket Reference
UBR2 UBR Peptide Positive/shallow 153
SPOP BTB Peptide Shallow 154,155
KLHL3 BTB Peptide Negative/shallow 156
KLHL12 BTB Peptide Shallow 95
KLHL20 BTB Peptide Negative/shallow 157
KLHDC2 BTB Peptide Negative/deep 96
SPSB1 SPRY Peptide Shallow 158
SPSB2 SPRY Peptide Shallow 158–160
SPSB4 SPRY Peptide Shallow 160
SOCS2 SOCS Peptide Negative/shallow 92
SOCS6 SOCS Peptide Negative 94
FBXO4 FBXO Protein Shallow 161
FBXO31 FBXO Peptide Negative 162
BTRC FBXW Peptide Negative 163
FBW7 FBXW Peptide Negative 164,165
CDC20 APC/C Peptide Shallow 166
CDC20 APC/C Small molecule Hydrophobic 167
ITCH HECT Peptide Shallow 168,169
PML TRIM Peptide Shallow 170
TRIM21 TRIM Peptide Shallow 171
TRIM24 TRIM Peptide Shallow 172
TRIM24 TRIM Small molecule Deep 173,174
TRIM33 TRIM Peptide Shallow 175
GID4 CTLH Peptide Positive/deep 98
3D: Three-dimensional; PROTAC: proteolysis-targeting chimera.
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classes, including E3 ubiquitin ligases (https://www.eubo-
pen.org). The consortium comprises 22 different partner 
organizations, including universities, research institutes, 
European Federation of Pharmaceutical Industries and 
Associations (EFPIA) members, and small and medium-
sized enterprises (SMEs). EUbOPEN will operate under the 
auspices of a longer-term initiative called Target 2035.99,100
Other Target-Based Approaches
HTS is a well-known strategy to identify compounds that 
bind to target proteins; however, even large compound 
libraries (e.g., composed of millions of compounds, as 
available to large pharmaceutical companies) can only 
cover a tiny area of chemical space. To address this issue, 
DNA-encoded libraries (DELs) are an attractive combina-
torial approach that allows extension of chemical space 
coverage by small molecules and so is increasingly being 
applied to drug discovery in academia and pharmaceutical 
companies.101 One of the most widely applied methods to 
construct DELs is a split-and-pool approach. This type of 
DEL usually consists of two to four building blocks, 
enabling a theoretical single DEL that can have more than 
a billion compounds in some cases. One of the limitations 
of DELs is that the libraries can be screened with only cell-
free assay systems (e.g., against recombinant purified tar-
get proteins); therefore, it is challenging to measure the 
biological activity of hit compounds directly in a cellular 
environment. Screening target proteins in vitro means that 
DELs are a method of choice for the identification of bind-
ing ligands, irrespective of their functionality in bioassays 
or in cells. To this end, DELs are potentially highly suited 
as an approach to screen for new E3 ligase binders for 
developing PROTACs. Indeed, several pharmaceutical and 
protein degradation biotech companies, including Arvinas, 
Nurix, and Kymera, have disclosed that they are pursuing 
applications of DEL technologies (either developed as pro-
prietary in house, or via partnerships) to find new E3 ligase 
ligands. Perhaps curiously, however, no peer-reviewed 
publication has yet emerged describing the application of 
DEL technology to identify novel E3 ligase ligands for 
PROTACs, potentially suggesting specific challenges with 
targeting the protein surface and protein–protein interac-
tion binding sites that are required to be targeted on E3 
ligases. In contrast, novel DELs designed for targeting E3 
ligases, for instance covalent DELs,102,103 should provide 
an attractive approach to discover selective E3 binders and 
develop novel PROTACs. In fact, some pharmaceutical 
companies have announced increasing activity and invest-
ment to expand the repertoire of E3 ligases for PROTACs 
by DEL technology.
Phage display technology is one of the greatest ways to 
obtain peptide ligands for target proteins for which natural 
substrates and ligands have not been identified.104 In this 
technology, a randomized synthetic DNA library is inserted 
into a phage coat protein gene in bacteriophages to express 
peptides of desired length onto their coat proteins. The 
obtained “phage library” is incubated with immobilized 
target (protein, cDNA, antibody, enzyme, small molecule, 
etc.) and then washed out to remove unbound phages. The 
remaining phages are eluted and then used to infect bacte-
rial cells to amplify phages for the next cycle. After a few 
rounds of selection, phages that express high-affinity pep-
tides to the target are accumulated and could be sequenced 
to identify these peptides. This approach is also suitable 
to isolate appropriate peptide ligands for developing 
PROTACs for the same reason as with DELs. It requires 
additional medicinal chemistry to develop peptidomimetic 
ligands and improve drug-like properties; however, pep-
tidic PROTACs could be developed rapidly based on pep-
tides identified by phage display as chemical tools to study 
the recruitment of specific E3 ligases for targeted protein 
degradation.
In addition to allowing identification of linear peptides, 
phage display, yeast display, and other display technologies 
can be used to identify and develop cyclic and macrocyclic 
peptides too. Cyclic peptides are structurally constrained 
macrocycles that have emerged as a promising class of mol-
ecules to bind to and so target proteins, including targeting 
protein surfaces and protein–protein interactions in targets 
once considered unligandable and so undruggable.105,106 
Due to their constrained “locked” nature and potential to 
form intramolecular hydrogen bonds, cyclic peptides can 
exhibit greater permeability and higher metabolic stability 
than their linear counterparts, making them attractive as 
chemical tools to probe novel biology.107,108
Several approaches are being pursued to develop macro-
cyclic peptides as bioactive or binding/affinity agents. 
These include rational design,109 DNA-templated synthesis 
and selection,110 phage-encoded combinatorial display of 
bicyclic peptides,111,112 and messenger RNA (mRNA) dis-
play followed by cyclization.113
Among the mRNA display methods available, the 
Random Nonstandard Peptides Integrated Discovery 
(RaPID) system involves peptide spontaneous cyclization 
and selection, and allows flexible incorporation of nonpro-
teinogenic amino acids. RaPID has demonstrated success 
at generating cyclic peptide ligands of high binding affinity 
and specificity for a variety of protein targets.114,115 In an 
early related application, cyclic peptides were identified 
targeting E6AP, a HECT E3 ligase target involved in 
p53-dependent apoptosis.116
Phenotypic Screening Approach
Molecular glues are attractive starting points for identifying 
applicable E3 ligases for PROTACs; however, the previ-
ously identified molecular glues, immunomodulatory drugs 
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(IMiDs) and sulfonamides, were found serendipitously. For 
instance, indisulam is a representative compound in the 
sulfonamide-type molecular glues that was discovered by 
cell growth inhibitory assay and cell cycle analysis without 
understanding of its mode of action at that time.117 The 
major challenge for the discovery of new molecular glues is 
a limited availability of rational strategies for their identifi-
cation or design that would induce proteasomal degradation 
of target proteins. Recently, strategies and approaches have 
been developed to begin to address these shortcomings. 
Słabicki et al. analyzed cytotoxicity data of 4518 clinical 
and preclinical small molecules against 578 cancer cell 
lines to show correlation between cytotoxicity and expres-
sion level of 499 E3 ligase mRNA.118 They found that pan 
cyclin-dependent kinase (CDK) inhibitor CR8 shows a 
level of correlation between cytotoxicity of each cell line 
and the mRNA levels in the same cell line of CDK12 and 
DNA damage-binding protein-1 (DDB1), which is a com-
ponent of DDB1–CUL4 E3 ligase complexes. Treatment of 
CR8 was found to induce degradation of cyclin K without 
changing the cyclin K mRNA level, suggesting that cyclin 
K degradation might occur as a result of its ubiquitination 
via DDB1-associated ubiquitin–proteasome machineries. 
The cocrystal structure of the cyclin K–CDK12–CR8–
DDB1 complex revealed that CDK12 formed extensive 
protein–protein interactions to DDB1 directly, essentially 
mimicking interactions formed by DDB1-associated sub-
strate recognition subunits (also known as DCAFs), and 
that CR8 acted as a molecular glue to enhance this weak-
affinity interaction, bringing it to sufficient stability to 
induce efficient ubiquitination and proteasomal degradation 
of the CDK12-associated subunit cyclin K. In another study, 
Mayor-Ruiz et al. performed focused screens in ned-
dylation-impaired cell lines that had the neddylation E2 
conjugating enzyme Ube2M knocked out, to bias identifi-
cation of cytotoxic compounds that were preferentially 
active and so required neddylation-competent CRL machin-
eries. These screens enabled the authors to find novel che-
motypes as hits that were shown to act as molecular glue 
degraders via DCAF15–CAPERα and DDB1–CDK12–
CyclinK, akin to the mode of action of indisulam-like sul-
fonamides and CR8.119 These reports not only provide a 
first step toward more systematic approaches to identify 
small molecules that act as molecular glues, but also expand 
opportunities to find molecules that hit new E3 ligases in an 
unbiased manner, in those cases allowing the discovery of 
molecules that do not interact with the substrate recognition 
subunit proteins of Cullin RING ligases directly.
Phenotypic screens both provide the opportunity to find 
molecular glues and can be applied to discover bifunctional 
PROTAC compounds. For example, anchoring a covalent 
warhead to a ligand of a target protein provides another way 
to fish for novel E3 ligases that could be applied to 
PROTACs, as demonstrated in the case of the studies 
identifying DCAF16 and RNF4 as described in the section 
titled “Other E3 Ligases for PROTACs: RNF4, RNF114, 
DCAF16, and AhR.”79,81 Envisaged extensions of these 
approaches will involve synthesizing bifunctional mole-
cules that consist of a ligand for a disease-relevant protein, 
linked to different covalent warheads. Cell lines treated 
with these compounds and subsequently assessed for degra-
dation of POI represent a strategy to find novel covalently 
targeted E3 ligases.120
Future Perspective
Enabled by the discoveries of high-quality, crystallographi-
cally defined ligands for the E3 ligases VHL and CRBN, 
PROTACs have had a meteoric resurgence in the limelight, 
a remarkable development that has culminated in the first 
PROTAC degraders being demonstrated as safe and effica-
cious in the clinic.6,7 These advances have marked a signifi-
cant step forward and provided added confidence to drug 
hunters to embark on campaigns to develop PROTAC-
based drugs for unmet medical needs, including cancers. It 
remains challenging, however, to efficiently degrade many 
proteins using PROTACs. This is because PROTACs need 
to form stable ternary complexes between the E3 ligase and 
POI, and PROTAC-induced protein–protein interactions 
are important to facilitate efficient and selective target ubiq-
uitination and degradation.121,122 It follows that for given 
target–E3 ligase combinations, it may be challenging to 
achieve ternary complexes of sufficient stability and suit-
able properties that make them productive to downstream 
target ubiquitination and degradation.
The lack of suitable chemical matters for most E3 ligases 
and undruggable disease targets represents a major stum-
bling block to our ability to efficiently and effectively navi-
gate degrader drug space. Therefore, there is no doubt that 
enabling more E3 ligases with new chemistry and new 
binding ligands becomes an important objective that, when 
met, will augment the applications and potential of 
PROTACs to expand in scope to more disease-relevant tar-
get proteins. In forecasting novel E3 ligase discovery, we 
believe that the variety of approaches we have highlighted 
in this review should help to enrich the armory of E3 ligases 
that can become amenable to PROTAC drug development. 
The tremendous progress seen in recent years in technolo-
gies such as atomic-level cryogenic electron microscopy 
(cryo-EM) analysis,123,124 refined protein modeling by next-
generation computer-aided design and artificial intelli-
gence,125 and others are expected to accelerate this area of 
research dramatically. Using disease-, tissue-, and/or organ-
specific E3 ligases to develop PROTACs should allow for 
more cell-type-selective degraders, to aid better understand-
ing of targets’ biology and usher in safer drugs with reduced 
dose-limiting toxicities. To evaluate protein degradation 
activities more accurately, however, it is essential to better 
14 SLAS Discovery 00(0)
understand not only the localization of target proteins and 
E3 ligases but also their dynamics in cells under disease-
oriented microenvironments. In addition, there is still a long 
way to go to develop rational, predictive, a priori strategies 
to design PROTACs that form stable and cooperative ter-
nary complexes between a target protein and E3 ligase. 
Nonetheless, comprehensive in silico approaches, for 
instance molecular dynamics simulation and prediction 
models by artificial intelligence, aided by enormous com-
putational capability (supercomputers and on-demand 
cloud computing), are ripe for supporting PROTAC design 
in the future.
PROTACs represent an emerging modality in drug dis-
covery, as a prominent example of a new class of multispe-
cific drugs that form proximity-induced protein–protein 
interactions between targeted proteins.126,127 Novel 
degrader molecules are now being developed hot on the 
heels of PROTACs, and they differentiate by the mecha-
nism of action or the targets being recruited.128 These 
approaches include monomeric protein degraders,129,130 
autophagy-targeting chimeras (AUTACs),131 biological 
PROTACs (bioPROTACs),132 lysosome-targeting chime-
ras (LYTACs),133 autophagosome-tethering compound 
(ATTEC),134 and others. PROTACs remain frontrunners in 
the targeted protein degradation space, and their rise to 
popularity has affected the emergence of other modalities 
of induced proximity pharmacology, including bifunc-
tional molecules recruiting enzymatic activities beyond E3 
ubiquitin ligases, such as protein phosphatases135 and pro-
tein kinases.136 It could not be a more exciting time to start 
finding novel binders for E3 ligases and other unliganded 
target proteins.
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